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Background: The frequency of ocular surface squamous neoplasias (OSSNs) has been increasing in populations with a high
prevalence of infection with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) and infection with
human papillomavirus (HPV). We aimed to quantify the association between HIV/AIDS and HPV infection and OSSN, through
systematic review and meta-analysis.
Methods: The articles providing data on the association between HIV/AIDS and/or HPV infection and OSSN were identified in
MEDLINE, SCOPUS and EMBASE searched up to May 2013, and through backward citation tracking. The DerSimonian and Laird
method was used to compute summary relative risk (RR) estimates and 95% confidence intervals (95% CI). Heterogeneity was
quantified with the I2 statistic.
Results: HIV/AIDS was strongly associated with an increased risk of OSSN (summary RR¼ 8.06, 95% CI: 5.29–12.30, I2¼ 56.0%, 12
studies). The summary RR estimate for the infection with mucosal HPV subtypes was 3.13 (95% CI: 1.72–5.71, I2¼ 45.6%, 16 studies).
Four studies addressed the association between both cutaneous and mucosal HPV subtypes and OSSN; the summary RR
estimates were 3.52 (95% CI: 1.23–10.08, I2¼ 21.8%) and 1.08 (95% CI: 0.57–2.05, I2¼ 0.0%), respectively.
Conclusion: Human immunodeficiency virus infection increases the risk of OSSN by nearly eight-fold. Regarding HPV infection,
only the cutaneous subtypes seem to be a risk factor.
The term ocular surface squamous neoplasia (OSSN) comprises a
wide variety of lesions of the conjunctiva and cornea, ranging from
mild dysplasia to carcinoma in situ and, in a later stage, invasive
squamous cell carcinoma (SCC; Nagaiah et al, 2010; Di Girolamo,
2012).
Although OSSN are rare conditions, they are among the most
frequent ocular surface tumours (Grossniklaus et al, 1987), and an
increase in their frequency has been reported since the 1980s
(Chokunonga et al, 1999; Parkin et al, 1999; Wabinga et al, 2000),
especially in sub-Saharan Africa. This paralleled the spread of the
human immunodeficiency virus/acquired immunodeficiency
syndrome (HIV/AIDS) epidemic in this setting. Chronic immuno-
suppression is currently a well-accepted risk factor for OSSN
(Shields et al, 2011), although to our knowledge there are no
quantitative syntheses of the results linking HIV/AIDS with OSSN
based on a systematic review of the literature.
Risk factors other than HIV include fair skin, ocular pigmenta-
tion, smoking and exposure to solar ultraviolet radiation (Kiire and
Dhillon, 2006). Human papillomavirus (HPV) has been identified
in tumour specimens from several case series (Saegusa et al, 1995;
Moubayed et al, 2004; Ateenyi-Agaba et al, 2010; Chauhan et al,
2012) and an association between HPV infection and OSSN has
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also been suggested (Scott et al, 2002; Ateenyi-Agaba et al, 2004).
However, the specific contribution of the different mucosal and
cutaneous HPV subtypes has seldom been addressed in the same
study, as shown in a previous systematic review by de Koning et al
(2008), although no meta-analysis was conducted.
Therefore, we updated previous systematic reviews and/or meta-
analyses that addressed the association between HIV/AIDS and
HPV (cutaneous and mucosal subtypes) infections and OSSN.
MATERIALS AND METHODS
Search strategy. We searched MEDLINE (through PubMed),
EMBASE (through OVID) and SCOPUS, from inception to May
2013, to identify studies addressing the association between
infection with HIV and/or HPV and OSSN; the search expressions
are provided in the systematic review flowchart (Figure 1,
Supplementary Information). We also screened the lists of
bibliographic references of the original reports considered eligible
for the systematic review and review articles on these topics.
Selection of the studies. We aimed to select cohort, case–control
or cross-sectional analyses addressing the association between
infection with HIV and/or mucosal or cutaneous HPV and OSSN.
Studies should provide enough detail to characterise the popula-
tion, the methods involved to evaluate HIV and/or HPV infection
status and the outcomes under study.
The eligibility of the studies was independently assessed by two
researchers (HC and FC), in three consecutive steps, applying
predefined criteria. In the first step, the studies were excluded
considering only the information presented in the title and
abstract; when the abstract of a particular article was not available,
it was considered for further evaluation. In the second step, the full
texts of the articles not previously excluded were assessed to
determine their eligibility for the review, using the same set of
criteria. In the third step, the full texts were re-evaluated to
determine the eligibility for meta-analyses.
The exclusion criteria were the following: (1) reports not
evaluating human subjects (e.g. in vitro studies); (2) review articles,
guidelines, comments or conference abstracts; (3) OSSN case
reports or case series; (4) studies not providing a relative risk (RR)
estimate for the association between HIV and/or HPV infection
and OSSN, or the necessary information to compute it; (5) multiple
reports of the same data; (6) not providing enough information to
characterise the control population. There were no language
restrictions.
Among reports with overlapping samples, we selected those
providing data regarding the largest number of cases, with RR
estimates adjusted for the largest number of potential confounders
or presenting more detailed information regarding the sample
characteristics, by applying these criteria consecutively.
We excluded one study (McDonnell et al, 1986), conducted in
the United Sates because the methods used did not allow to
characterise the HPV subtypes involved. We further excluded
four studies more likely to have yielded biased estimates of
the association between HIV infection and OSSN because (1) controls
were recruited among subjects undergoing screening for HIV
infection (Waddell et al, 2010); (2) a standardised incidence ratio
was computed using the observed number of SCC of the conjunctiva
(SCCC) and the estimated number of all cases of eye cancer
(Mbulaiteye et al, 2006); (3) the outcome was ocular cancer, excluding
only retinoblastoma and neuroblastoma (Newton et al, 1995);
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Figure 1. Meta-analysis of the studies assessing the relation between HIV infection and OSSN. * indicates that this RR estimate was computed by
the authors of the present meta-analysis with data provided in the original report although the controls were frequency age- and sex-matched with
the cases; a sensitivity analysis excluding this study yielded a summary RR of 9.1 (95% CI: 6.1–13.6, I2¼ 43.8%). w indicates that when this study was
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(4) the control group only included AIDS-defining malignancies
(Ebughe et al, 2012); (5) compared the prevalence of HIV among
the SCCC cases with the prevalence of HIV of the general
population (Spitzer et al, 2009).
The decisions taken independently by the reviewers in each step
were compared and the discrepancies were resolved by consensus
or involving a third researcher (NL or CC).
Data extraction and meta-analysis. Data extraction was per-
formed independently by two researchers (HC and FC); non-
concordant outputs were discussed until consensus or involving a
third researcher (NL or CC).
A predefined form was used to collect information on the
following items: (1) year of publication; (2) country and region
where the sample was assembled; (3) characteristics of the cases
and controls (sample size, age distribution, procedures for recruit-
ment of the participants); (4) diagnostic methods used to assess the
HIV and HPV infection statuses; (5) subtypes of HIV and HPV
detected, whenever available; (6) RR estimates and corresponding
precision estimates, or the necessary information to compute them,
preferably adjusted for the largest number of possible confounders,
for the association between HIV/AIDS or different HPV subtypes,
namely cutaneous and mucosal (de Villiers et al, 2004), and OSSN;
(7) RR estimates for the association between HPV infection and
OSSN, by HIV infection status, whenever available. For the studies
including no infected cases among one group of subjects, we
estimated the odds ratio (OR) and respective 95% confidence
intervals (95% CI) using the metan command of STATA (Stata
Corp., College Station, TX, USA), which adds by default 0.5 to all
cells of the 2 2 table of the study (Harris et al, 2008).
We conducted meta-analyses for the association between HIV,
cutaneous HPV and mucosal HPV infections and OSSN. The
DerSimonian and Laird method was used to compute summary RR
estimates with 95% CI. Heterogeneity was quantified using the I2
statistic (Higgins and Thompson, 2002).
As pterygium and pingueculae have been suggested to be
associated with HPV infection (Reid and Dushku, 2003;
Di Girolamo, 2012), we conducted sensitivity analyses excluding
the studies with 410% of subjects with these conditions in
the control group (McDonnell et al, 1989; Tabrizi et al, 1997;
Dushku et al, 1999; Ateenyi-Agaba et al, 2004; Simbiri et al, 2010;
Carrilho et al, 2013).
Publication bias was assessed through visual inspection of funnel
plots and Egger’s regression asymmetry test (Sterne et al, 2000).
The statistical analysis was performed using STATA, version 9.2
(Stata Corp.).
RESULTS
HIV infection and OSSN. Twelve studies provided data to assess
the relation between HIV infection and OSSN (Kestelyn et al,
1990; Ateenyi-Agaba, 1995; Goedert and Cote, 1995; Waddell
et al, 1996; Newton et al, 2002; Porges and Groisman, 2003; Timm
et al, 2004; Chinogurei et al, 2006; Tornesello et al, 2006;
de Koning et al, 2008; Guech-Ongey et al, 2008; Ateenyi-Agaba
et al, 2010), of which 10 were conducted in Africa, mostly in
Uganda, and two in the United States. The subtype of HIV
involved was seldom available (Newton et al, 2002). With the
exception of the two studies conducted in the United States
(Goedert and Cote, 1995; Guech-Ongey et al, 2008), all were
case–control analyses. Only three studies provided RR estimates
adjusted for potential confounders (Newton et al, 2002; Guech-Ongey
et al, 2008; Ateenyi-Agaba et al, 2010), mostly age and sex.
Human immunodeficiency virus infection strongly increased
the risk of OSSN; the overall RR estimate was 8.06 (95% CI: 5.29–
12.30, I2¼ 56.0%; Figure 1). The visual inspection of the funnel
plot suggests the existence of publication bias, with smaller studies
with weaker associations being underrepresented (Figure 2),
although it is not statistically significant according to Egger’s
regression asymmetry test (P¼ 0.596).
In the study by Ateenyi-Agaba et al (2010), the OR was 5.6 (95%
CI: 1.5–20.3) for the comparison of AIDS patients with those
infected with HIV but without an AIDS diagnosis. The two
investigations conducted in the United States (Goedert and Cote,
1995; Guech-Ongey et al, 2008) showed that the risk of OSSN
among the HIV-infected varied with the time in relation to the
diagnosis of AIDS. In the study by Goedert and Cote (1995),
2 years after the diagnosis the ratio between observed and expected
SCCC cases was 196 (95% CI: 24–708), and Guech-Ongey et al
(2008) observed a stronger association in the period of  6 to þ 3
months relative to the AIDS onset.
People with AIDS were overrepresented in the cohorts of HIV-
infected subjects evaluated in the two studies from the United
States (Goedert and Cote, 1995; Guech-Ongey et al, 2008). Their
exclusion from the meta-analysis resulted in a summary RR of 7.17
(95% CI: 4.32–11.90, I2¼ 57.6%).
HPV infection and OSSN. Twenty two studies provided data to
assess the association between infection with mucosal and/or
cutaneous HPV subtypes and OSSN (Supplementary Information).
Five studies (Ateenyi-Agaba et al, 2004; Tornesello et al, 2006; de
Koning et al, 2008; Ateenyi-Agaba et al, 2010; Carrilho et al, 2013),
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Figure 2. Funnel plots of studies evaluating the association between human immunodeficiency virus (HIV) and mucosal human papillomavirus
(HPV) infection and OSSN.
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four conducted in Uganda and one in Mozambique, addressed
the association between infection with cutaneous subtypes
of HPV and OSSN. The summary RR was 3.82 (95% CI:
1.77–8.22, I2¼ 13.0%; Figure 3), similar among HIV-infected
and non-infected subjects (Figure 4). Excluding two studies
(Ateenyi-Agaba et al, 2004; Carrilho et al, 2013) in which
pterygia or pinguecula patients represented 410% of the
controls, the summary RR was 3.52 (95% CI: 1.23–10.08,
I2¼ 21.8%).
Sixteen studies, conducted in 10 countries, provided data to
assess the association between mucosal HPV infection, mostly with
subtypes 16 and 18, and OSSN (McDonnell et al, 1989; Adachi
et al, 1995; Saegusa et al, 1995; Waddell et al, 1996; Karcioglu and
Issa, 1997; Tabrizi et al, 1997; Palazzi et al, 2000; Newton et al,
2002; Scott et al, 2002; Tornesello et al, 2006; Auw-Haedrich et al,
2008; de Koning et al, 2008; Ateenyi-Agaba et al, 2010; Asadi-
Amoli et al, 2011; Chauhan et al, 2012; Carrilho et al, 2013); the
summary RR was 3.13 (95% CI: 1.72–5.71, I2¼ 45.6%; Figure 3).
When excluding the three studies having 410% of controls with
pterygia or pinguecula (McDonnell et al, 1989; Tabrizi et al, 1997;
Carrilho et al, 2013), the summary RR estimate was 2.50 (95% CI:
1.35–4.65, I2¼ 37.4%).
Four studies, conducted in Germany (Guthoff et al, 2009), India
(Sen et al, 2007), Thailand (Tulvatana et al, 2003) and the United
States (Dushku et al, 1999) did not find any mucosal HPV-positive
specimen, neither among cases nor among controls, and therefore
could not be considered for meta-analysis (Supplementary
Information).
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The visual inspection of the funnel plot suggests publication
bias, as small studies yielding negative associations between
infection with mucosal HPV subtypes and OSSN are under-
represented (Figure 2). This is supported by the results of Egger’s
regression asymmetry test (P¼ 0.023).
When considering only the results of the four studies (Tornesello
et al, 2006; de Koning et al, 2008; Ateenyi-Agaba et al, 2010; Carrilho
et al, 2013) providing data also for cutaneous subtypes of HPV, the
summary RR was 1.08 (95% CI: 0.57–2.05, I2¼ 0.0%; Figure 3).
The association between mucosal subtypes of HPV and the
OSSN was similar according to the participants’ HIV infection
status, although this information could be obtained only from a
subsample of the studies (Figure 4).
DISCUSSION
This study confirms that HIV infection strongly increases the risk of
OSSN. Although the evidence regarding the role of HPV infection is
less conclusive, the results from studies that evaluated both cutaneous
and mucosal subtypes of HPV suggest that only the cutaneous HPV
subtypes are associated with an increased risk of OSSN.
We conducted a comprehensive systematic review, using three
of the most important biomedical databases and backward citation
tracking of review articles and eligible reports. A large number of
potential relevant bibliographic references were screened, not only
from MEDLINE-indexed publications but also from journals with
smaller impact. Nevertheless, the summary RR may be over-
estimated because of publication bias, although not compromising
the validity of our conclusion of a positive and strong association
between HIV infection and OSSN. Immunossupression has a
central role in this relation (Holkar et al, 2005; Grulich et al, 2007),
and its later stage in patients with AIDS is probably reflected in a
stronger association with OSSN. Unfortunately, the data addres-
sing this specific aspect was scarce, and a quantitative synthesis of
the results on the association between AIDS and OSSN could not
be accomplished. Differences between studies regarding its design
and the proportion of people with AIDS and on highly active
antiretroviral therapy could have contributed to the observed
heterogeneity of results, although the I2 statistic decreased just
slightly when the cohort studies conducted in the United States
were excluded in a sensitivity analysis.
Regarding the relation between HPV and OSSN, only five
studies provided data to assess the specific effect of cutaneous
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Figure 4. Meta-analyses of the studies addressing the association between human papillomavirus (HPV) infection and ocular surface squamous
neoplasia (OSSN) by HIV status. * indicates that this RR estimate was computed by the authors of the present meta-analysis with data provided in
the original report, although the controls were frequency age- and sex-matched with the cases; w indicates that a sensitivity analysis excluding this
study yielded an overall RR of 2.66 (95% CI: 1.33–5.40, I2¼ 0.0%); z indicates that from this study RR estimates are available both for multiple and
single infection, and the latter was selected for meta-analysis because it was more common than multiple infections (among the HPV-infected,
54.5% were infected with a single type and the remaining with multiple); in a sensitivity analysis including the estimate for multiple infection
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subtypes, and this small number precludes a formal assessment of
the publication bias. Although we cannot rule out publication bias,
the inclusion of the estimate for single infection from the study of
Ateenyi-Agaba et al (2010) resulted in a conservative estimate of
the association between infection with cutaneous subtypes of HPV
and OSSN. In a sensitivity analysis including both estimates for
single and multiple infection, the summary RR estimate was 7.19,
95% CI: 2.52–20.50, I2¼ 60.1%), and the publication bias appears
less likely. On the other hand, it is clear that smaller studies yielded
stronger estimates of the association between HPV infection with
mucosal subtypes and OSSN. However, the four reports (Dushku
et al, 1999; Tulvatana et al, 2003; Sen et al, 2007; Guthoff et al,
2009) that did not detect HPV of mucosal subtypes neither in cases
nor in controls are not represented in the funnel plot, which is in
accordance with other case series that did not detect HPV of
mucosal subtypes in SCCC specimens (Eng et al, 2002; Manderwad
et al, 2009). Although the lack of sensitivity of the methods used to
assess infection status may contribute to spuriously low pre-
valences of HPV, these results argue against a strong role of the
mucosal subtypes of HPV in the aetiology of OSSN.
Considering that the association between HPV infection with
mucosal subtypes was weaker than that for cutaneous HPV,
especially when accounting for the results from the studies that
addressed the role of infection with both subtypes, our meta-
analysis adds to previous research (IARC Working Group on the
Evaluation of Carcinogenic Risks to Humans, 2012) evidence of a
stronger role of cutaneous HPV infection in the aetiology of OSSN.
Previous studies have reviewed the role of HIV and HPV
infections and the risk of SCCC (Newton, 1996; Sasco et al, 2010).
Regarding the former, Newton (1996) in 1996 combined the RR
estimates of four studies and provided a summary RR of 13.0 (95%
CI: 7.2–23.1). In addition, Sasco et al (2010) systematically
reviewed the available information on this topic, but they did
not perform a meta-analysis. Recently the evidence on this topic
was considered to be sufficient to establish HIV as an oncogenic
factor for conjunctival cancer (Bouvard et al, 2009). Our study
adds eight additional studies to the previous quantitative synthesis,
along with a formal assessment of the potential selection bias
underlying the summary estimate.
In 1996, Newton (1996) also described the proportion of
controls and SCCC cases infected with HPV in case series and
case–control studies. Our systematic review identified 18 more
studies for which it was possible to compare the frequency of HPV
infection among cases and a comparison group. More recently, de
Koning et al (2008) presented, together with their case–control
study, a systematic review of the literature on the association
between HPV infection and SCCC, including studies published up
to 2008. The present systematic review included six additional
studies (Auw-Haedrich et al, 2008; Guthoff et al, 2009; Ateenyi-
Agaba et al, 2010; Asadi-Amoli et al, 2011; Chauhan et al, 2012;
Carrilho et al, 2013) published since then, although only one
provided information that could be used to assess the association
between infection with cutaneous subtypes of HPV and SCCC. Our
study also adds to the previous reports the assessment of a potential
interaction between HIV and HPV infections, although further
research is needed for more robust conclusions on this issue, and the
demonstration that the published evidence on the association
between mucosal HPV and SCCC overestimates the true association.
The conclusions of our review are naturally limited by the
methodological quality of the original studies. Although some
investigations involved consecutive patients attending some health-
care facility (Kestelyn et al, 1990; Ateenyi-Agaba, 1995; Newton
et al, 2002; Scott et al, 2002; de Koning et al, 2008; Ateenyi-Agaba
et al, 2010; Waddell et al, 2010), others provided relatively poor
descriptions of the patients studied, precluding a systematic
assessment of potential biases. It was not possible to characterise
the type of HIV infection in the vast majority of the studies,
which would improve the characterisation of the populations
being studied, and the assessment of type-specific effects. Future
research should also address the potential effect modification by
sunlight exposure and provide RR estimates adjusted for the main
confounders. The studies also involved analytical methods for the
detection of HPV and/or HIV with different sensitivity and
specificity. An example is the study by Simbiri et al (2010), where
31 out of 36 participants were HPV-positive using immunohis-
tochemistry methods; however, HPV DNA was amplified with
PCR in only 24 participants. Moreover, although in most studies
the detection of HPV was based on viral DNA amplification by
PCR, some searched for a large spectrum of mucosal subtypes,
whereas others only aimed to detect specific subtypes.
The ORs computed for the studies that did not detect HPV
infection among subjects of the control group represent inaccurate
estimates of the true association between HPV infection and OSSN.
Although the option for adding 0.5 to all cells of the contingency
table yields OR estimates with very wide 95% CI, and therefore not
expected to have a meaningful impact on the summary RR estimates,
these results suggest a strong association between HPV infection and
OSSN, and being able to consider them in the meta-analysis allows a
much more efficient summary of the available evidence.
Human immunodeficiency virus was shown to be a strong risk
factor for OSSN. A recent systematic review aiming at evaluating
the effect of interventions for treating SCCC among HIV-infected
patients showed that no randomised controlled trial had been
conducted in HIV-positive patients, and the evidence on currently
available treatments comes from analyses of case reports or cases
series (Gichuhi and Irlam, 2013). Further research is needed on
strategies to improve early diagnosis and treatment of OSSN
among HIV-positive patients.
Although evidence-based treatments for OSSN are needed,
prevention of its occurrence cannot be overemphasised. Ocular
surface squamous neoplasias are not so rare conditions in many
African settings (Chokunonga et al, 1999; Parkin et al, 1999) where
access to highly active antiretroviral therapy is far from universal
(Tanser et al, 2013). Improving the access to HAART, especially in
settings with concomitant high prevalence of HPV infection, has
the potential to substantially decrease the burden of OSSN (Holkar
et al, 2005; Bekele et al, 2013). Moreover, the two prophylactic
HPV vaccines commercialised in the last few years contain virus-
like particles for four HPV mucosal subtypes (6, 11, 16 and 18),
and much has been speculated on the impact of HPV vaccination
in the prevention of eye disease (Hughes et al, 2008). Taking into
account our results and the subtypes of HPV infection that can be
prevented by the vaccine, the incidence of OSSN should not be
expected to decrease because of vaccination.
In conclusion, HIV infection increases the risk of OSSN by
eight-fold, whereas regarding the effects of HPV infection the
available evidence suggests that only the cutaneous HPV subtypes
are associated with an increased risk of OSSN.
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